Advertisement

Cancer Chemotherapy and Pharmacology

, Volume 26, Issue 6, pp 409–414 | Cite as

Pharmacokinetics of the recombinant fusion protein DAB486IL-2 in animal models

  • Patricia Bacha
  • Serene Forte
  • Nasim Kassam
  • Jenifer Thomas
  • Donna Akiyoshi
  • Cory Waters
  • Jean Nichols
  • Michael Rosenblum
Article

Summary

The kinetics of the in vitro cytotoxicity of DAB486IL-2, a genetically engineered fusion protein containing a portion of diphtheria toxin and human interleukin-2, were examined in the C91/PL cell line, which constitutively expresses IL-2 receptors. Maximal inhibition of protein synthesis was observed by 4–6 h after DAB486 IL-2 addition at a concentration of 300 ng/ml. The tissue distribution, urinary excretion, and plasma pharmacokinetics of DAB486IL-2 in the rat and its plasma pharmacokinetics in the monkey were also examined. In rats the primary site of distribution of [35S]-DAB486IL-2 outside the vasculature appears to be the liver, followed by the kidney, spleen, and lung. Persistence of radioactive material in the liver and urinary excretion of metabolic degradation products suggest that labeled protein is metabolized by hepatic tissue. Following i.v. bolus administration of DAB486IL-2, the initial serum half-life for both the rat and the monkey was approximately 5 min. The overall clearance rate of drug for the two species differed, with DAB486IL-2 being cleared from circulation 2–3 times more rapidly in the monkey. Presence of high levels of neutralizing antibodies to diphtheria toxin in the rat significantly influenced the clearance of bioactive DAB486IL-2. However, the question as to whether the presence of in vitro biological activity for the molecule is masked by the presence of antibodies cannot be clearly answered.

Keywords

Diphtheria Toxin Bolus Administration Neutralize Antibody Titer Leucine Incorporation Engineer Fusion Protein 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bacha P, Williams DP, Waters C, Williams JM, Murphy JR, Strom TB (1988) Interleukin-2 receptor-targeted cytotoxicity: interleukin-2 receptor-mediated action of a diphtheria toxin-related interleukin-2 fusion protein. J Exp Med 167: 612PubMedCrossRefGoogle Scholar
  2. 2.
    Diamantstein T, Osawa H (1986) The interleukin-2 receptor, its physiology and a new approach to a selective immunosuppressive therapy by anti-interleukin-2 receptor monoclonal antibodies. Immunol Rev 92: 5PubMedCrossRefGoogle Scholar
  3. 3.
    Eksborg S, Ehrsson H, Ekqvist B (1982) Protein binding of anthraquinone glycosides, with special reference to Adriamycin. Cancer Chemother Pharmacol 10: 7PubMedCrossRefGoogle Scholar
  4. 4.
    Figlin RA, Itri LM (1988) Anti-interferon antibodies: a perspective. Semin Hematol 25 [Suppl 3]: 9PubMedGoogle Scholar
  5. 5.
    Kiyokawa T, Shirono K, Hattori T, Nishimura H, Yamaguchi K, Nichols JC, Strom TB, Murphy JR, Takatsuki K (1989) Cytotoxicity of interleukin-2 toxin toward lymphocytes from patients with adult T-cell leukemia. Cancer Res 49: 4042PubMedGoogle Scholar
  6. 6.
    Lorberboum-Galski H, FitzGerald DJP, Chaudhary W, Adhya S, Pastan I (1988) Cytotoxic activity of an interleukin-2-Pseudomonas exotoxin chimeric protein produced inE. coli. Proc Natl Acad Sci USA 85: 1922PubMedCrossRefGoogle Scholar
  7. 7.
    Paolozzi F, Zamkoff K, Doyle M, Konrad M, Bradley EC, Rudolf A, Newman N, Gullo J, Scalzo A, Poiesz B (1989) Phase I trial of recombinant interleukin-2 and recombinant beta-interferon in refractory neoplastic diseases. J Biol Response Mod 8: 122PubMedGoogle Scholar
  8. 8.
    Paolozzi FPO, Ehrlich GD, Bacha P, Nichols JC, Bhagavati S, Ratner L, Poiesz BJ (1990) Effect of recombinant interleukin-2-diphtheria toxin fusion protein on fresh and cultured HTLV-I-infected T-lymphocytes: inhibition of viral load as assessed by polymerase chain reaction (in press)Google Scholar
  9. 9.
    Popovic M, Lanze-Wanzin G, Sarin PS, Mann D, Gallo RC (1983) Transformation of human umbilical cord blood T-cells by human T-cell leukemia/lymphoma virus. Proc Natl Acad Sci USA 80: 5402PubMedCrossRefGoogle Scholar
  10. 10.
    Poste G, Kirsh R (1983) Site-specific (targeted) drug delivery in cancer therapy. Bio/Technology 1: 869CrossRefGoogle Scholar
  11. 11.
    Sands H, Loveless SE (1989) Biodistribution and pharmacokinetics of recombinant human [125I]-interleukin-2 in mice. Int J Immunopharmacol 11: 411PubMedCrossRefGoogle Scholar
  12. 12.
    Shain SA, Huyot RI (1988) Antiandrogen effects in models of androgen-responsive cancer. J Steroid Biochem 31: 711PubMedCrossRefGoogle Scholar
  13. 13.
    Siegall CB, Chaudhary VK, FitzGerald DJ, Pastan I (1988) Cytotoxic activity of an interleukin-6-Pseudomonas exotoxin fusion protein on human myeloma cells. Proc Natl Acad Sci USA 85: 9738PubMedCrossRefGoogle Scholar
  14. 14.
    Talmadge JE, Black PL, Tribble H, Pennington R, Bowersox O, Schneider M, Phillips H (1987) Preclinical approaches to the treatment of metastatic disease: therapeutic properties of rH TNF, rH IFN-gamma and rH IL-2. Drugs Exp Clin Res 13: 327PubMedGoogle Scholar
  15. 15.
    Vitetta ES. Fulton RJ, May RD, Till M, Uhr JW (1987) Redesigning nature’s poisons to create anti-tumor reagents. Science 238: 1098PubMedCrossRefGoogle Scholar
  16. 16.
    Waldmann TA (1988) Multichain interleukin-2 receptor: a target for immunotherapy in lymphoma. J Natl Cancer Inst 81: 914CrossRefGoogle Scholar
  17. 17.
    Waters CA, Schimke PA, Snider CE, Itoh K, Smith KA, Nichols JC, Strom TB, Murphy JR (1990) Interleukin-2 receptor targeted cytotoxicity receptor binding requirements for productive entry of a diphtheria toxin-related interleukin-2 fusion protein into cells. Eur J Immunol (in press)Google Scholar
  18. 18.
    Williams DP, Parker K, Bacha P, Bishai W, Borowski M, Genbauffe F, Strom TB, Murphy JR (1987) Diphtheria toxin receptor binding domain substitution with interleukin-2: genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein. Protein Eng 1: 493PubMedCrossRefGoogle Scholar
  19. 19.
    Zimmer AM, Rosen ST, Spies SM, Goldman-Leikin R, Kazikiewicz JM, Silverstein EA, Kaplan EH (1988) Radioimmunotherapy of patients with cutaneous T-cell lymphoma using an iodine-131-labeled monoclonal antibody: analysis of retreatment following plasmapheresis. J Nucl Med 29: 174PubMedGoogle Scholar
  20. 20.
    Zucker DR, Murphy JR (1984) Monoclonal analysis of diphtheria toxin: I. Localization of epitope and neutralization of cytotoxicity. Mol Immunol 21: 785PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 1990

Authors and Affiliations

  • Patricia Bacha
    • 1
  • Serene Forte
    • 1
  • Nasim Kassam
    • 1
  • Jenifer Thomas
    • 1
  • Donna Akiyoshi
    • 1
  • Cory Waters
    • 1
  • Jean Nichols
    • 1
  • Michael Rosenblum
    • 2
  1. 1.Seragen, Inc.HopkintonUSA
  2. 2.Department of Clinical Immunopharmacology and Biological TherapyUniversity of Texas M. D. Anderson Cancer CenterHoustonUSA

Personalised recommendations